Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
17.15 x 10 18.98 x 1
Post-market by (Cboe BZX)
18.50 -0.05 (-0.27%) 04/25/25 [NASDAQ]
17.15 x 10 18.98 x 1
Post-market 18.75 +0.25 (+1.35%) 18:03 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
17.96
Day High
18.97
Open 18.25
Previous Close 18.55 18.55
Volume 1,012,100 1,012,100
Avg Vol 863,740 863,740
Stochastic %K 88.73% 88.73%
Weighted Alpha -3.26 -3.26
5-Day Change +2.92 (+18.74%) +2.92 (+18.74%)
52-Week Range 12.01 - 34.13 12.01 - 34.13
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,068,047
  • Shares Outstanding, K 111,485
  • Annual Sales, $ 605,220 K
  • Annual Income, $ -168,630 K
  • EBIT $ -170 M
  • EBITDA $ -185 M
  • 60-Month Beta 0.65
  • Price/Sales 3.27
  • Price/Cash Flow N/A
  • Price/Book 5.34

Options Overview Details

View History
  • Implied Volatility 59.49% ( -7.04%)
  • Historical Volatility 61.33%
  • IV Percentile 12%
  • IV Rank 16.92%
  • IV High 116.02% on 10/15/24
  • IV Low 47.98% on 01/27/25
  • Put/Call Vol Ratio 0.11
  • Today's Volume 1,314
  • Volume Avg (30-Day) 489
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 18,328
  • Open Int (30-Day) 14,831

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.49
  • Number of Estimates 5
  • High Estimate -0.33
  • Low Estimate -0.72
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -58.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.81 +24.92%
on 04/09/25
Period Open: 18.77
19.25 -3.87%
on 04/24/25
-0.27 (-1.44%)
since 03/25/25
3-Month
14.81 +24.92%
on 04/09/25
Period Open: 26.33
26.47 -30.10%
on 01/30/25
-7.83 (-29.74%)
since 01/24/25
52-Week
12.01 +54.04%
on 04/26/24
Period Open: 12.23
34.13 -45.80%
on 12/18/24
+6.27 (+51.27%)
since 04/25/24

Most Recent Stories

More News
Why NovoCure Stock Skyrocketed This Week

Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session. This muted reaction...

COMP : 7.37 (+0.14%)
NVCR : 18.50 (-0.27%)
Why NovoCure Stock Leaped 4% Higher Today

Thursday morning NovoCure (NASDAQ: NVCR) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess...

NFLX : 1,101.53 (+0.42%)
NVDA : 111.01 (+4.30%)
NVCR : 18.50 (-0.27%)
NovoCure Surpasses Q1 Expectations

NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.

NVCR : 18.50 (-0.27%)
NovoCure: Q1 Earnings Snapshot

NovoCure: Q1 Earnings Snapshot

NVCR : 18.50 (-0.27%)
Why NovoCure Stock Was Withering on Wednesday

Cancer-focused biotech NovoCure (NASDAQ: NVCR) was the focus of a stock price target cut on Wednesday, and investors weren't particularly happy about it.

NFLX : 1,101.53 (+0.42%)
NVDA : 111.01 (+4.30%)
NVCR : 18.50 (-0.27%)
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why

Explore the exciting world of NovoCure (NASDAQ: NVCR) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential...

NVCR : 18.50 (-0.27%)
NovoCure (NVCR) Q4 2024 Earnings Call Transcript

NVCR earnings call for the period ending December 31, 2024.

NVCR : 18.50 (-0.27%)
NovoCure Q4 EPS Misses, Revenue Matches

NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.

NVCR : 18.50 (-0.27%)
MRK : 82.74 (+3.63%)
ZLAB : 32.00 (-5.33%)
RHHBY : 39.5200 (-0.58%)
NovoCure: Q4 Earnings Snapshot

NovoCure: Q4 Earnings Snapshot

NVCR : 18.50 (-0.27%)
Why NovoCure Stock Was Winning Big This Week

Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum...

NVCR : 18.50 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 20.00
2nd Resistance Point 19.49
1st Resistance Point 18.99
Last Price 18.50
1st Support Level 17.98
2nd Support Level 17.47
3rd Support Level 16.97

See More

52-Week High 34.13
Fibonacci 61.8% 25.68
Fibonacci 50% 23.07
Fibonacci 38.2% 20.46
Last Price 18.50
52-Week Low 12.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective